scholarly journals A Real-World Single-Centre Study of Patients with Diabetic Macular Oedema Who Wore a Home-Use Sleep Mask (Noctura 400) for One Year

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Ulrich Meyer-Bothling ◽  
Oliver Meyer-Bothling ◽  
Marika Pinney
Keyword(s):  
Patient Compliance ◽  
Real World ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Single Centre ◽  
Single Centre Study ◽  
Functional Consequences ◽  
Clinic Practice ◽  
One Year ◽  
High Level

A “Real-World” single-centre observational study was carried out to analyse the effects of enhanced patient interaction with the use of the Noctura 400 sleep mask on a group of 26 diabetics displaying diabetic retinopathy (DR) and diabetic macular oedema (DMO), of which 24 completed the study. We hoped to find if patient compliance could be maintained and to determine the anatomical and functional consequences of consistent mask wear. While this study was ongoing, COVID-19 impacted on normal eye clinic practice, allowing an unexpected analysis of the effects of this disruption to the clinical system on mask wear and disease progress. Throughout the whole study, outcomes were positive, with a high level of consistent patient use of the mask, above 74% up to and beyond 1 year. Even during the COVID-19 1st lockdown in England, the patients maintained a 65% nightly light mask compliance. Statistically significant improvements in maculopathy, including cyst reduction (56.4% of eyes with cysts exhibited cyst shrinkage), and visual acuity (VA) improvement (42/48 eyes gained 5 letters or more) were observed and maintained to the end of the study. Anatomical improvement or stability was recorded in all but one study eye. This investigation shows that given that there is appropriate interaction with patients who are self-treating in home environment, a high level of patient compliance can be maintained, even while there are disruptions to the normal hospital clinic setup.

scholarly journals Quantitative Assessment of Choroidal Parameters in Patients with Various Types of Diabetic Macular Oedema: A Single-Centre Cross-Sectional Analysis

Biology ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 725
Author(s):  
Diana Anna Dmuchowska ◽  
Patryk Sidorczuk ◽  
Barbara Pieklarz ◽  
Joanna Konopińska ◽  
Zofia Mariak ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Choroidal Thickness ◽  
Subretinal Fluid ◽  
Diabetic Macular Oedema ◽  
Single Centre ◽  
Cross Sectional ◽  
Luminal Area ◽  
Single Centre Study ◽  
Diabetic Choroidopathy ◽  
Sectional Analysis

Diabetic macular oedema (DME) is an outcome of multiple, complex and not fully understood mechanisms. The aim of this study was to define the role of choroidopathy in the pathogenesis of various DME types. The retrospective cross-sectional single-centre study included 140 eyes from 105 patients with DME and 76 eyes from 52 non-diabetic controls. The eyes were stratified according to the type of DME: cystoid, diffuse, and with subretinal fluid. Optical coherence tomography-based choroidal parameters: thickness, volume, choroidal vascularity index (CVI), luminal area (LA), stromal area (SA), and total choroidal area (TCA) were compared. Eyes with DME, regardless of the type thereof, had lower choroidal thickness, volume, and CVI values than the controls. Further, the eyes with some specific DME types differed significantly from the controls in terms of LA and SA. While the eyes with various DME types did not differ significantly in terms of their choroidal thickness, volume and CVI, some between-group differences were found in LA, SA and TCA. Diabetic choroidopathy seems to play a role in the development of DME but is less likely involved in the pathogenesis of specific types thereof.

Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry

Eye ◽  
2021 ◽  
Author(s):  
Sanjeeb Bhandari ◽  
David Squirrell ◽  
Vuong Nguyen ◽  
Nancy Wang ◽  
Jane M. Wells ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
One Year

scholarly journals Real-world management and long-term outcomes of diabetic macular oedema with good visual acuity

Eye ◽  
2019 ◽  
Vol 34 (6) ◽  
pp. 1108-1115
Author(s):  
Kieu-Yen Luu ◽  
Mutaal M. Akhter ◽  
Blythe P. Durbin-Johnson ◽  
Ala Moshiri ◽  
Steven Tran ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Real World ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Long Term Outcomes ◽  
Good Visual Acuity

P104 One year failure rates for de novo ventriculo-peritonealshunts in under 3- month-old children

2019 ◽  
Vol 90 (3) ◽  
pp. e50.1-e50
Author(s):  
E Bentley ◽  
R Ved ◽  
A Amato-Watkins ◽  
J Lang ◽  
G Zilani ◽  
...  
Keyword(s):  
Infection Rate ◽  
De Novo ◽  
Descriptive Statistics ◽  
Infection Rates ◽  
Older Children ◽  
Single Centre ◽  
Single Centre Study ◽  
One Year ◽  
Shunt Survival ◽  
Shunt Infections

ObjectivesHistorically VPS failure and infection rates are higher for neonates than for older children. We compared our one year VPS failure and infection rates in under 3-month-olds with those of older children.DesignA retrospective, single centre study comparing 1 year survival and infection rates of VPS in under 3-month-olds verses older children.Subjects58 children under 3 months of age underwent VPS insertion between January 2007 and December 2016.MethodsData was collected by three independent reviewers from electronic files and case notes. Data was analysed using descriptive statistics and one year shunt survival curves were produced.ResultsFor children under 3 months there was a 29.3% one-year shunt failure rate, of which 2 were shunt infections (3.4%). In patients greater than 3 months, the shunt malfunction rate was 23.4% and the infection rate was 4.3%. There were no shunt-related mortalities in either group.ConclusionsChildren under 3-months-old undergoing VPS insertion should not automatically expect an increased 1 year failure or infection rate compared with older children. Reasons for this may be increased sub-specialisation, improved neonatal care and use of antibiotic impregnated catheters.

scholarly journals Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series

2020 ◽  
Vol 5 (1) ◽  
pp. e000484
Author(s):  
Muna Ahmed ◽  
Christine Putri ◽  
Hibba Quhill ◽  
Fahd Quhill
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Macular Oedema ◽  
Case Series ◽  
Diabetic Macular Oedema ◽  
Fluocinolone Acetonide ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
The Mean

ObjectiveTo assess the real-world effectiveness and safety of single injection of a fluocinolone acetonide (FAc) implant in previously treated patients with recurrent diabetic macular oedema (DMO) over a 36-month follow-up period.Methods and AnalysisThis is a retrospective study conducted at a single ophthalmology department at the Royal Hallamshire Hospital, Sheffield, UK. Data were collected using electronic medical records to identify all patients treated with a FAc implant for DMO between March 2014 and November 2014, followed with a 36-month clinic follow-up. Outcomes measured included mean change in best-recorded visual acuity (BRVA) and central macular thickness (CMT) over the period of 36 months, treatment burden pre-implant and post-implant, and functional and anatomical responder rates.ResultsTwenty-six eyes (n=22 patients) were treated with single intravitreal FAc implant followed with 36 months of follow-up. At 24 and 36 months, 86.4% and 75.0% of patients maintained or gained vision post-FAc implant in routine clinical practice. The mean BRVA increased from 41.8 to 54.6 letters at month 24 and 45.8 letters at month 36, with 50.0% and 33.3% of patients achieving a ≥15 letter improvement at months 24 and 36, respectively. The mean CMT reduced from 600.8 µm at baseline to 351.0 µm and 392.5 µm at months 24 and 36, respectively. Overall, a mean of one treatment every 13.33 months post-FAc implant (vs 3.24 months pre-FAc implant) was reported. Eleven eyes had an increased intraocular pressure of ≥10 mm Hg and 12 eyes had an increase to ≥25 mm Hg from baseline.ConclusionThese results further support the effectiveness and safety of FAc implant in previously treated patients with persistent or recurrent DMO in a real-world clinical practice.

Long‐term follow‐up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four‐year real‐world study

2019 ◽  
Vol 98 (4) ◽  
pp. 360-367
Author(s):  
Elisabet Granstam ◽  
Andreas Rosenblad ◽  
Aseel Modher Raghib ◽  
Therese Granström ◽  
Jan W. Eriksson ◽  
...  
Keyword(s):  
Growth Factor ◽  
Real World ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Antivascular Endothelial Growth Factor ◽  
Long Term Follow Up ◽  
Endothelial Growth Factor ◽  
Growth Factor Treatment
Sign in / Sign up

Export Citation Format

Share Document